Senores Pharmaceuticals Ltd. · NSE:SENORES
Senores Pharmaceuticals — Merger or Acquisition (December 2025)
6 slides from Senores Pharmaceuticals's merger presentation, December 2025
Slide 1: Acquisition of Apnar Pharma Private Limited
Acquisition of Apnar Pharma Private Limited
Slide 2: Deal Contours
5 Deal Contours Senores to acquire Apnar Pharma Private Limited & 5 ANDA’s • Apnar Pharma, incorporated on 12th December 2014, is a privately held pharmaceutical company specializing in the licensing, development, and manufacturing of generic About Apnar Pharma formulations for regulated markets lik
Slide 3: About the Manufacturing Facility
About the Manufacturing Facility Key Highlights of the Plant Manufacturing facility commenced in 2021 & USFDA Approval received in September 2022 2 land parcel available of total land area of ~49,250 Sq. Mts. Facility constructed on 1 plot (~4,500 Sq. Mts) with construction of ~40,000 Sq. Ft. La
Slide 4: Strategic Rationale & Synergies
Strategic Rationale & Synergies Compliment our strong presence in the US and Immediate access to regulated markets like UK, Canada, and other Regulated Markets through existing approvals and infrastructure Revenue and cost synergies through cross-selling and shift of select products Expansion of pro
Slide 5: Management Commentary
5 Management Commentary Commenting on the acquisition, Mr. Swapnil Shah, Promoter & Managing Director of Senores, said: “This acquisition marks a significant milestone in accelerating the growth trajectory of Senores Pharmaceuticals Limited. The facility will not only enhance our manufacturing capac
Slide 6: Senores Pharmaceuticals Limited
SENORES PHARMACEUTICALS LIMITED CONTACT US Senores Pharmaceuticals Limited Strategic Growth Advisors Private Limited CIN: L24290GJ2017PLC100263 CIN: U74140MH2010PTC204285 Mr. Deval Shah – Whole Time Director & CFO Mr. Sagar Shroff / Mr. Tanay Shah sagar.shroff@sgapl.net / tanay.shah@sgapl.net invest
Senores Pharmaceuticals — Merger or Acquisition (December 2025) on 6ix